Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)
China
· Delayed Price · Currency is CNY 25.54
+0.28 (1.11%)
May 14, 2025, 2:45 PM CST
SHE:300255 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,031 | 1,397 | 2,327 | 2,941 | 2,354 | Upgrade
|
| Other Revenue | - | 13.25 | 9.65 | 27.3 | 9.76 | Upgrade
|
| Revenue | 1,031 | 1,410 | 2,336 | 2,968 | 2,364 | Upgrade
|
| Revenue Growth (YoY) | -26.92% | -39.63% | -21.29% | 25.56% | 14.11% | Upgrade
|
| Cost of Revenue | 864.82 | 1,733 | 1,315 | 1,246 | 743.43 | Upgrade
|
| Gross Profit | 165.99 | -322.77 | 1,021 | 1,722 | 1,620 | Upgrade
|
| Selling, General & Admin | 220.34 | 630.71 | 739.69 | 1,220 | 1,098 | Upgrade
|
| Research & Development | 47.19 | 158.82 | 145.01 | 150.63 | 127.54 | Upgrade
|
| Other Operating Expenses | -4.91 | 17.24 | 22.02 | 26.77 | 23.71 | Upgrade
|
| Operating Expenses | 262.61 | 822.15 | 913.23 | 1,398 | 1,252 | Upgrade
|
| Operating Income | -96.62 | -1,145 | 107.99 | 324.06 | 368.78 | Upgrade
|
| Interest Expense | - | -96.41 | -93.04 | -62.29 | -55.81 | Upgrade
|
| Interest & Investment Income | 33.26 | 1.85 | 1.99 | 1.3 | 1.64 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 4.76 | 6.69 | -4.4 | -6.47 | Upgrade
|
| Other Non Operating Income (Expenses) | -123.83 | -13.67 | -12.8 | -10.13 | -8.99 | Upgrade
|
| EBT Excluding Unusual Items | -187.18 | -1,248 | 10.84 | 248.54 | 299.15 | Upgrade
|
| Impairment of Goodwill | - | -1.78 | -1.78 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.06 | -0 | -0.09 | -0.11 | -0.02 | Upgrade
|
| Asset Writedown | -69.83 | - | -0.27 | - | - | Upgrade
|
| Other Unusual Items | - | 18.49 | 9.41 | 11.98 | 2.42 | Upgrade
|
| Pretax Income | -257.08 | -1,232 | 18.12 | 260.41 | 301.56 | Upgrade
|
| Income Tax Expense | 6.95 | 16.46 | 7.96 | 29.15 | 50.42 | Upgrade
|
| Earnings From Continuing Operations | -264.03 | -1,248 | 10.16 | 231.26 | 251.14 | Upgrade
|
| Minority Interest in Earnings | 14.55 | 7.94 | 7.36 | 2.31 | 1.7 | Upgrade
|
| Net Income | -249.48 | -1,240 | 17.51 | 233.57 | 252.84 | Upgrade
|
| Net Income to Common | -249.48 | -1,240 | 17.51 | 233.57 | 252.84 | Upgrade
|
| Net Income Growth | - | - | -92.50% | -7.62% | 12.23% | Upgrade
|
| Shares Outstanding (Basic) | 924 | 919 | 876 | 934 | 936 | Upgrade
|
| Shares Outstanding (Diluted) | 924 | 919 | 876 | 934 | 936 | Upgrade
|
| Shares Change (YoY) | 0.58% | 4.91% | -6.27% | -0.23% | -0.24% | Upgrade
|
| EPS (Basic) | -0.27 | -1.35 | 0.02 | 0.25 | 0.27 | Upgrade
|
| EPS (Diluted) | -0.27 | -1.35 | 0.02 | 0.25 | 0.27 | Upgrade
|
| EPS Growth | - | - | -92.00% | -7.41% | 12.50% | Upgrade
|
| Free Cash Flow | -183.37 | -205.6 | -428.1 | -305.21 | -383.36 | Upgrade
|
| Free Cash Flow Per Share | -0.20 | -0.22 | -0.49 | -0.33 | -0.41 | Upgrade
|
| Dividend Per Share | - | - | 0.005 | 0.026 | - | Upgrade
|
| Dividend Growth | - | - | -80.77% | - | - | Upgrade
|
| Gross Margin | 16.10% | -22.88% | 43.71% | 58.01% | 68.55% | Upgrade
|
| Operating Margin | -9.37% | -81.17% | 4.62% | 10.92% | 15.60% | Upgrade
|
| Profit Margin | -24.20% | -87.93% | 0.75% | 7.87% | 10.70% | Upgrade
|
| Free Cash Flow Margin | -17.79% | -14.58% | -18.32% | -10.28% | -16.22% | Upgrade
|
| EBITDA | -24.27 | -1,071 | 164.93 | 379.86 | 424.06 | Upgrade
|
| EBITDA Margin | -2.35% | -75.91% | 7.06% | 12.80% | 17.94% | Upgrade
|
| D&A For EBITDA | 72.35 | 74.25 | 56.94 | 55.8 | 55.28 | Upgrade
|
| EBIT | -96.62 | -1,145 | 107.99 | 324.06 | 368.78 | Upgrade
|
| EBIT Margin | -9.37% | -81.17% | 4.62% | 10.92% | 15.60% | Upgrade
|
| Effective Tax Rate | - | - | 43.94% | 11.19% | 16.72% | Upgrade
|
| Revenue as Reported | - | 1,410 | 2,336 | 2,968 | 2,364 | Upgrade
|
Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.